Sales have surged since the launch of the drugs - up 26% in 2022, 31% in 2023, and the company projects another leap of at least 22% this year
The researchers found that GLP-1 receptor agonist initiation was associated with a reduced risk for disorders related to alcohol use, cannabis use, cocaine use, nicotine use, opioid use, and other SUDs compared with initiation of SGLT-2 inhibitors (hazard ratios, 0.82, 0.86, 0.80, 0.80, 0.75, and 0.87, respectively) and with a reduced risk for the composite outcome of all incident SUDs (hazard ratio, 0.86)
Results can be maintained with continued therapy and healthy lifestyle habits as recommended by your provider
David Oliak, MD, and PA Allison Mollet, PA-C, have worked together since 2006 first in Dr
The initial response at 2.5 mg often diminishes over time, making escalation necessary to maintain efficacy